Sartorius Aktiengesellschaft (SRT3) - Total Assets
Based on the latest financial reports, Sartorius Aktiengesellschaft (SRT3) holds total assets worth €9.87 Billion EUR (≈ $11.54 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SRT3 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Sartorius Aktiengesellschaft - Total Assets Trend (2002–2025)
This chart illustrates how Sartorius Aktiengesellschaft's total assets have evolved over time, based on quarterly financial data. Explore Sartorius Aktiengesellschaft strategic investment ratio to see how much of total assets are deployed in long-term investments.
Sartorius Aktiengesellschaft - Asset Composition Analysis
Current Asset Composition (December 2025)
Sartorius Aktiengesellschaft's total assets of €9.87 Billion consist of 18.2% current assets and 81.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €541.40 Million | 5.6% |
| Accounts Receivable | €291.70 Million | 3.0% |
| Inventory | €792.20 Million | 8.2% |
| Property, Plant & Equipment | €2.46 Billion | 25.3% |
| Intangible Assets | €1.83 Billion | 18.8% |
| Goodwill | €3.47 Billion | 35.7% |
Asset Composition Trend (2002–2025)
This chart illustrates how Sartorius Aktiengesellschaft's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SRT3 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sartorius Aktiengesellschaft's current assets represent 18.2% of total assets in 2025, a decrease from 49.7% in 2002.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2025, up from 3.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 7.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 35.7% of total assets.
Sartorius Aktiengesellschaft Competitors by Total Assets
Key competitors of Sartorius Aktiengesellschaft based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
West Pharmaceutical Services Inc
NYSE:WST
|
USA | $4.11 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Safe Orthopaedics SA
PA:ALSAF
|
France | €7.94 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
Sartorius Aktiengesellschaft - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.91 | 1.46 | 1.25 |
| Quick Ratio | 0.52 | 0.93 | 0.72 |
| Cash Ratio | 0.00 | 0.57 | 0.33 |
| Working Capital | €-189.70 Million | €678.10 Million | €323.80 Million |
Sartorius Aktiengesellschaft - Advanced Valuation Insights
This section examines the relationship between Sartorius Aktiengesellschaft's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.49 |
| Latest Market Cap to Assets Ratio | 0.96 |
| Asset Growth Rate (YoY) | -3.8% |
| Total Assets | €9.72 Billion |
| Market Capitalization | $9.32 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Sartorius Aktiengesellschaft's assets close to their book value (0.96x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: Sartorius Aktiengesellschaft's assets decreased by 3.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sartorius Aktiengesellschaft (2002–2025)
The table below shows the annual total assets of Sartorius Aktiengesellschaft from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €9.72 Billion ≈ $11.36 Billion |
-3.82% |
| 2024-12-31 | €10.10 Billion ≈ $11.81 Billion |
+3.56% |
| 2023-12-31 | €9.76 Billion ≈ $11.40 Billion |
+39.81% |
| 2022-12-31 | €6.98 Billion ≈ $8.16 Billion |
+22.46% |
| 2021-12-31 | €5.70 Billion ≈ $6.66 Billion |
+21.30% |
| 2020-12-31 | €4.70 Billion ≈ $5.49 Billion |
+65.15% |
| 2019-12-31 | €2.84 Billion ≈ $3.33 Billion |
+12.56% |
| 2018-12-31 | €2.53 Billion ≈ $2.95 Billion |
+9.97% |
| 2017-12-31 | €2.30 Billion ≈ $2.69 Billion |
+31.07% |
| 2016-12-31 | €1.75 Billion ≈ $2.05 Billion |
+21.97% |
| 2015-12-31 | €1.44 Billion ≈ $1.68 Billion |
+12.95% |
| 2014-12-31 | €1.27 Billion ≈ $1.49 Billion |
+8.35% |
| 2013-12-31 | €1.17 Billion ≈ $1.37 Billion |
+9.65% |
| 2012-12-31 | €1.07 Billion ≈ $1.25 Billion |
+11.12% |
| 2011-12-31 | €963.84 Million ≈ $1.13 Billion |
+19.33% |
| 2010-12-31 | €807.74 Million ≈ $944.33 Million |
-1.55% |
| 2009-12-31 | €820.42 Million ≈ $959.16 Million |
-5.15% |
| 2008-12-31 | €865.00 Million ≈ $1.01 Billion |
+10.34% |
| 2007-12-31 | €783.93 Million ≈ $916.50 Million |
+107.75% |
| 2006-12-31 | €377.34 Million ≈ $441.15 Million |
+2.97% |
| 2005-12-31 | €366.45 Million ≈ $428.41 Million |
+2.66% |
| 2004-12-31 | €356.96 Million ≈ $417.32 Million |
-2.52% |
| 2003-12-31 | €366.19 Million ≈ $428.12 Million |
-8.02% |
| 2002-12-31 | €398.14 Million ≈ $465.47 Million |
-- |
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell cult… Read more